Please leave us your contact details so we can reach out to you as soon as we can.
Resources
RMD – Market expectations are for Uniform ROA to expand, but management may have concerns about growth, product reach, and supply chain challenges
April 11, 2022
ResMed Inc. (RMD) currently trades above corporate and historical averages relative to Uniform earnings, with a 34.2x Uniform P/E (Fwd. V/E’).
At these levels, markets are pricing in expectations for Uniform ROA to expand to 69%, accompanied by 3% Uniform asset growth.
Meanwhile, analysts expect Uniform ROA to improve to 43% in 2023, accompanied by 8% Uniform asset growth.
If sustained going forward, these levels would imply a stock price closer to $185, representing approximately 25% equity downside for the firm.
You don’t have access to the Valens Research Premium Application.
To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email client.relations@valens-research.com.
Please fill out the fields below so that our client relations team can contact you
Or contact our Client Relationship Team at 630-841-0683